Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway

Xie, Xi; Li, Wenyuan; Lan, Tian; Liu, Weihua; Peng, Jing; Huang, Kaipeng; Huang, Juan; Shen, X. Y.; Liu, Peiqing; Huang, Heqing

doi:10.1507/endocrj.k11e-024

Cited by 45 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, another study in 3T3-L1 adipocytes reported that the BBR-induced glucose uptake pathway was distinct from insulin and was not completely inhibited by ERK inhibitor nor was GLUT-4 or GLUT-1 expression altered (Zhou et al 2007). In addition, BBR treatment was shown to improve insulin resistance via increased expression of Akt in alloxan-induced diabetic C57BL/6 mice and it increased insulin receptor substrate-2 mRNA expression in nonalcoholic fatty liver disease rat liver (Xie et al 2011;Xing et al 2011). Thus, even though the downstream pathways regulating glucose uptake may be different, it is likely that BBR mediates its anti-hyperglycemic effect through activation of the AMPK pathway.…”

Section: Page 5 Of 39mentioning

confidence: 99%

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies

Chang

Chen

Hatch

2015

Biochem. Cell Biol.

123

View full text Add to dashboard Cite

The incidence of type 2 diabetes is increasing rapidly worldwide, and the development of novel anti-diabetic drugs is emerging. However, most anti-diabetic drugs cannot be used in patients with hepatic dysfunction, renal disease, and heart disease, which makes pharmacological therapy of type 2 diabetes complicated. Despite continued introduction of novel agents, the search for an ideal drug that is useful as both a hypoglycemic agent and to reduce diabetes-related complications remains elusive. Berberine is an isoquinoline alkaloid extract that has shown promise as a hypoglycemic agent in the management of diabetes in animal and human studies. Mechanistic studies have revealed beneficial effects of berberine on diabetes-related complications. Although there have been few clinical reports of the anti-diabetic effects of berberine, little documentation of adverse effects in humans positions it as a potential candidate drug to treat type 2 diabetes. In the present review, the anti-diabetic mechanism of berberine, its effect on diabetes-related complications, and its recent use in human clinical studies is highlighted. In addition, we summarize the different treatments for type 2 diabetes in adults and children.

show abstract

Section: Page 5 Of 39mentioning

confidence: 99%

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies

Chang

Chen

Hatch

2015

Biochem. Cell Biol.

123

View full text Add to dashboard Cite

show abstract

“…3) Xie et al 4) and Khan et al 5) found that hepatic glycogen content decreased in insulin-resistant mice.…”

mentioning

confidence: 99%

Fucosylated Chondroitin Sulfate from Sea Cucumber in Combination with Rosiglitazone Improved Glucose Metabolism in the Liver of the Insulin-Resistant Mice

Chang

Wang

et al. 2013

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

“…18 4. Alkaloids such as isoboldine (36), norisoboldine (37), thaliporphine (38), corytuberine (39), reticuline (40), and taspine (41) (Fig. 10) present in the crude extract of Croton lechleri (leaves and latex).…”

Section: Future Directionsmentioning

confidence: 99%

“…36 Xie and coworkers revealed that berberine upregulates Akt, possibly via an insulin signaling pathway, eventually lowering high blood glucose in alloxaninduced diabetic mice. 37 Shen and coworkers demonstrated that berberine exerts antidiabetic action by activating cyclic adenosine monophosphate protein kinase and targeting insulin gene. 38 It also decreases the postprandial plasma glucose levels of streptozotocin-diabetic rats by inhibiting the increased activities of intestinal disaccharidases and elevating plasma insulin levels.…”

mentioning

confidence: 99%

Alkaloids as Aldose Reductase Inhibitors, with Special Reference to Berberine

Gupta

Singh

Jaggi

2014

The Journal of Alternative and Complementary Medicine

View full text Add to dashboard Cite

Aldose reductase is the rate-limiting enzyme of the polyol pathway that leads to conversion of glucose to sorbitol. Its increased activity, which results in abnormal activation of the polyol pathway, is implicated in the development of long-term complications of diabetes mellitus. Different plant species and their active components have shown potent in vitro and in vivo aldose reductase inhibitory activity. Among different phyto-constituents, alkaloids that contain isoquinoline/bis(isoquinoline)and related ring structures (such as berberine, palmatine, coptisine, and jateorrhizine) have shown very potent aldose reductase inhibitory activity. The structural activity relationship has revealed the importance of hydrophobic and hydrophilic groups of isoquinoline/bis(isoquinoline)for binding to an enzyme. The dioxymethylene group in the D ring (hydrophobic group) of these alkaloids binds tightly to the site adjacent to the anionic binding site (active site), while the methoxyl groups (polar) bind to the site adjacent to the nicotinamide ring of the coenzyme. On the basis of these findings, it may be proposed that the presence of isoquinoline/bis(isoquinoline)ring structures is the most important requirement for alkaloids to behave as potent aldose reductase inhibitors. Thus, other plants may also be screened for the same activity. The present review discusses these isoquinoline/bis(isoquinoline)-based alkaloids as aldose reductase inhibitors that may be used to manage diabetic complications and may substitute for the chemically synthesized aldose reductase inhibitors.

show abstract

Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway

Cited by 45 publications

References 35 publications

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies

Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies

Fucosylated Chondroitin Sulfate from Sea Cucumber in Combination with Rosiglitazone Improved Glucose Metabolism in the Liver of the Insulin-Resistant Mice

Alkaloids as Aldose Reductase Inhibitors, with Special Reference to Berberine

Contact Info

Product

Resources

About